Skip to content
DraconiticResearch
Search Sources API
181,686 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BYJHLT open

Limiting collateral damage: Nosocomial infections in patients with temporary mechanical circulatory support.

  • Ryan Dodge1
  • Nicolas Kumar2
  • Jonathan Tang3
  • Amit Bardia2
  1. 1Division of Cardiothoracic Anesthesiology, Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA.
  2. 2Mass General Brigham Department of Anesthesiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  3. 3Department of Anesthesia, Critical Care and Pain Medicine, Ohio State University Wexner Medical Center, Columbus, OH.
Read full textPDFDOICite

Abstract

The use of temporary mechanical circulatory support (tMCS) and extracorporeal membrane oxygenation (ECMO) for patients with cardiopulmonary compromise is on the rise. While these tMCS systems provide life-saving interventions, they also pose a significant risk of nosocomial infections, which are associated with higher mortality rates. Patients receiving tMCS are critically ill and require intensive care, increasing their vulnerability to infections. Common nosocomial infections include bloodstream infections (BSI) and ventilator-associated pneumonia (VAP) in patients with ECMO and wound-related complications in patients with microaxial temporary ventricular assist devices (tVADs). Key preventative measures include the incorporation of sound ICU practices such as chlorhexidine washes, minimizing disconnections, instituting VAP bundles, and promoting enteral nutrition. The practice of continuing prophylactic antibiotics while patients are on ECMO is not routinely recommended. While treatment strategies hinge primarily on antibiotics, ensuring adequate therapeutic levels of antibiotics is challenging and may contribute to suboptimal response to systemic antibiotics in these patients. A strategy of early liberation of patients from ECMO and conversion to temporary ventricular support (temporary LVAD, RVAD, or both) may promote early extubation and patient mobilization. Whether this strategy independently reduces infectious complications remains unknown. This review examines the epidemiology and etiology of nosocomial infections in patients receiving tMCS, summarizes current prevention and treatment strategies, and discusses the impact of infection on clinical outcomes.

Related

  1. Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials
    Osama Odeh, Mariam Al-Bayati, Ali Abdulrazzaq +2
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  2. Mechanical circulatory support strategy in post-myocardial infarction ventricular septal defect repair.
    Caroline A Magro, Caroline Snyder, Katherine Phillips +4
    JTCVS openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  3. Mechanical circulatory support devices in heart failure: a narrative review of current evidence, clinical applications, complications, and future directions
    Ruirui Zhu, Fangyuan Zhang, Yudong Peng +1
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Update in short-term mechanical circulatory support: indications, devices and complications
    Jose María Moreno-Coca, Eva Moreno-Monterde, Antoni Manzano +2
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossref
  5. The right ventricle as the Achilles' heel: tricuspid regurgitation and right heart failure in the era of mechanical circulatory support
    Wentao Wu, Shuohao Wang, Gaojun Xu +5
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{dodge2026limiting,
  title = {{Limiting collateral damage: Nosocomial infections in patients with temporary mechanical circulatory support.}},
  author = {Ryan Dodge and Nicolas Kumar and Jonathan Tang and Amit Bardia},
  journal = {JHLT open},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jhlto.2026.100696},
  url = {https://europepmc.org/article/MED/42903899},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Limiting collateral damage: Nosocomial infections in patients with temporary mechanical circulatory support.
AU  - Ryan Dodge
AU  - Nicolas Kumar
AU  - Jonathan Tang
AU  - Amit Bardia
PY  - 2026
DA  - 2026/09/21
JO  - JHLT open
DO  - 10.1016/j.jhlto.2026.100696
UR  - https://europepmc.org/article/MED/42903899
AB  - The use of temporary mechanical circulatory support (tMCS) and extracorporeal membrane oxygenation (ECMO) for patients with cardiopulmonary compromise is on the rise. While these tMCS systems provide life-saving interventions, they also pose a significant risk of nosocomial infections, which are associated with higher mortality rates. Patients receiving tMCS are critically ill and require intensive care, increasing their vulnerability to infections. Common nosocomial infections include bloodstream infections (BSI) and ventilator-associated pneumonia (VAP) in patients with ECMO and wound-related complications in patients with microaxial temporary ventricular assist devices (tVADs). Key preventative measures include the incorporation of sound ICU practices such as chlorhexidine washes, minimizing disconnections, instituting VAP bundles, and promoting enteral nutrition. The practice of continuing prophylactic antibiotics while patients are on ECMO is not routinely recommended. While treatment strategies hinge primarily on antibiotics, ensuring adequate therapeutic levels of antibiotics is challenging and may contribute to suboptimal response to systemic antibiotics in these patients. A strategy of early liberation of patients from ECMO and conversion to temporary ventricular support (temporary LVAD, RVAD, or both) may promote early extubation and patient mobilization. Whether this strategy independently reduces infectious complications remains unknown. This review examines the epidemiology and etiology of nosocomial infections in patients receiving tMCS, summarizes current prevention and treatment strategies, and discusses the impact of infection on clinical outcomes.
SN  - 2950-1334
ER  -